Skip to main content
68th Annual Scientific Meeting Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Red Recording
Red Recording
Sig Meeting
Sig Meeting

Therapeutics (Industry)

(T 32) A phase 3, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of zavegepant for the acute treatment of migraine in Asian adults

    Presenting Author(s)

  • Jeremias Antinew, MD

    Clinical Development Medical Senior Director
    Pfizer Inc.
    Unionville, Connecticut, United States

    • Non-presenting author(s)

  • Robert J. Fountaine, n/a

    Global Clinical Lead - CGRP Migraine Franchise
    Pfizer Inc., New York, NY, USA
    Groton, Connecticut, United States

    • Non-presenting Author(s)

  • SY

    Shengyuan Yu, n/a

    Director
    Chinese PLA General Hospital, Beijing, China
    Beijing, Beijing, United States

  • HM

    Heui-Soo Moon, MD, PhD

    Department of Neurology, Kangbuk Samsung Hospital, Sungkyuwnkwan University School of Medicine, Seoul, Korea, United States

  • JW

    Jing Wang, n/a

    Pfizer R&D, Beijing, China, United States

  • PW

    Panpan Wang, n/a

    Pfizer R&D, Shanghai, China, United States

  • HZ

    Hua Zhu, n/a

    Pfizer R&D, Shanghai, China, United States

  • TF

    Terence Fullerton, n/a

    Pfizer, Groton, CT, USA, United States